

Express Mail No.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (10-03)  
Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ ) 0.00

## Complete if Known

Application Number	10/620,520
Filing Date	07/16/2003
First Named Inventor	Adrien R. Beaudoin
Examiner Name	
Art Unit	1623
Attorney Docket No.	850865.90015

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number  
Deposit  
Account  
Name

17-0055

Quarles & Brady LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$ ) 0.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent	-20* =	X	0.00
Multiple Dependent	-3** =	X	0.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ ) 0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ ) 0.00

## SUBMITTED BY

(Complete if applicable)


Name (Print/Type)	Nicholas J. Seay	Registration No. (Attorney/Agent)	27,386	Telephone	608/251-5000
Signature		Date	Feb 9, 2004		

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


371196

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: Feb 9, 2004

  
Nicholas J. Seay

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Adrien R. Beaudoin  
Fernand-Pierre Gendron  
Efrat Halbfinger  
Bilha Fischer

Date: Feb. 9, 2004

Serial No.: 10/620,520

Group Art Unit: 1623

Filed: 07/16/2003

Examiner:

For: C8-SUBSTITUTED PURINE NUCLEOTIDE  
ANALOGS AND THEIR USE AS INHIBITORS OF  
NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASES

File No.: 850865.90015

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents  
P O Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a completed Form PTO-1449 listing documents that the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

No fee is believed due, but should a fee be due please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

  
Nicholas J. Seay  
Reg. No.: 27,386  
Attorney for Applicants  
QUARLES & BRADY LLP  
P.O. Box 2113  
Madison, WI 53701

TEL 608/251-5000  
FAX 608/251-9166

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

850865.90015

Application Number

10/620,520

Applicant(s)

BEAUDOIN, A.L. et al.

Filing Date

July 16, 2003

Group Art Unit

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	PATENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	U.S. 6,312,662 B1	11/06/2001	Erion et al.			

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	2.	Burnstock, G., Campbell, G., Bennett, M., and Holman, M.E. Innervation of the Guinea-Pig Taenia Coli: are there intrinsic inhibitory nerves which are distinct from sympathetic nerves? Int. J. Neuropharmacol 3: 163-166, 1964.
	3.	Burnstock, G. Evolution of the autonomic innervation of visceral and cardiovascular systems in vertebrates. Pharmacol. Rev. 21 (4): 247-324, 1969.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>850865.90015</b>	Application Number <b>10/620,520</b>
		Applicant(s) <b>BEAUDOIN, A.L. et al.</b>	
		Filing Date <b>July 16, 2003</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
	4.	Su, C., Bevan, J.A. and Burnstock, G. [3H] adenosine triphosphate: release during stimulation of enteric nerves. Science 173(994): 336-338, 1971.
	5.	Langer, S.Z., and Pinto, J.E.B. Possible involvement of a transmitter different from norepinephrine in the residual responses to nerves stimulation of the cat nictitating membrane after pretreatment with reserpine. J. Pharmacol. Exp. Ther. 196(3): 697-713, 1976.
	6.	Burnstock, G. Purinergic receptor. J. Theor. Biol. 62 (2): 491-503, 1976.
	7.	Von Kugelsen, I., and Starke, K. Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol. Sci. 12(9): 319-324, 1991.
	8.	Westfall, D.P., Sedaa, K.O., Shinozuka, K., Bjur, R.A., and Buxton, I.L.O. ATP as a Cotransmitter Ann. NY Acad. Sci. 603: 300-310, 1990.
	9.	Burnstock, G. Neural nomenclature. Nature 229(5282): 282-283, 1971.
	10.	Burnstock, G. A basis for distinguishing two types of purinergic receptors. In: Cell membrane receptors for drugs and hormones: A multidisciplinary approach. (Eds. R.W. Straub and L. Bolis), Raven press, New York. Pp. 107-118, 1978.
	11.	Fredholm, B.B., Abbracchio, M.P., Burnstock, G., Daly, J.W., Harden, T.K., Jacobson, K.A., Leff, P., and Williams, M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46(2): 143-156, 1994.
	12.	Gendron et al. ATP diphosphohydrolase inhibitors: novel perspectives. Poster Abstract, p. 327 from conference Ecto-ATPases and Related Ectonucleotidases (June 1999).
	13.	Juul, B., Plesner, L., and Aalkjaer, C. Effects of ATP and related nucleotides on the tone of isolated rat mesenteric resistance arteries. J. Pharmacol. Exp. Therap. 264: 1234-1240, 1993.
	14.	Motte, S., Communi, D., Piroton, S., Boeynaems, J.M. Involvement of multiple receptors in the actions of extracellular ATP: the examples of vascular endothelial cells. Int. J. Biochem. Cell Biol. 27: 1-7, 1995.
	15.	Rongen, G.A., Floras, J.S., Lender, J.W.M., Thien, T., and Smits, P. Cardiovascular pharmacology of purines. Clin. Sci. 92: 13-24, 1997.


EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

850865.90015

Application Number

10/620,520

Applicant(s)

BEAUDOIN, A.L. et al.

Filing Date

July 16, 2003

Group Art Unit

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Abstract, Title, Date, Pertinent Pages, Etc.)

- |     |   |
|-----|---|
| 16. | Dubyak, G.R., and El-Moatassim, C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am. J. Physiol. 265: C577-C606, 1993.   |
| 17. | Johnson, C.R., and Hourahi, S.M.O. Contractile effects of uridine 5'-triphosphate in the rat duodenum. Br. J. Pharmacol. 113(4): 1191-1196, 1994.   |
| 18. | Pennanen, M.F., Bass, B.L., Dziki, A.J., and Harmon, J.W. Adenosine differential effect on blood flow to subregions of the upper gastrointestinal tract. J. Surg. Res. 56(5): 461-465, 1994.  |
| 19. | Strohmeier, G.R., Reppert, S.M., Lencer, W.I., and Madana, J.L. The A2b adenosine receptor mediated cAMP responses to adenosine receptor agonists in human intestinal epithelia. J. Biol. Chem. 270(5): 2387-2394, 1995.                |
| 20. | Hancock, D.L., and Coupar, I.M. Functional characterization of the adenosine receptor mediating inhibition of peristalsis in the rat jejunum. Br. J. Pharmacol 115(5): 739-744, 1995.   |
| 21. | Sarna, S.K. Gastrointestinal longitudinal muscle contractions. Am. J. Physiol. 265(1pt1): G156-G164, 1993.  |
| 22. | Baricordi, O.R., Ferrari, D., Melchiorri, L., Chiozzi, P., Hanau, S., Chiari, E., Rubini, M., and Di Virgilio, F. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87(2): 682-690, 1996.     |
| 23. | Di Virgilio, F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol. Today 16(11): 524-528, 1995.  |
| 24. | Ventura, M.A., and Thomopoulos, P. ADP and ATP activate distinct signaling pathways in human promonocytic U-937 cells differentiated with 1,25-dihydroxy-vitamin D3. Mol. Pharmacol 47: 104-114, 1995.                                  |
| 25. | Biffen, M., and Alexander, D.R. Mobilization of intracellular Ca <sup>2+</sup> by adenine nucleotides in human T-leukaemia cells: evidence for ADP-specific and P2y-purinergic receptors. Biochem. J. 304:769-774, 1994.                |
| 26. | Apasov, S., Koshiba, M., Redegeld, F., and Sitokovsky, M.V. Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Immunol. Rev. 146: 5-19, 1995. |
| 27. | Hedge, S.S., Mandel, D.A., Wilford, M.R., Briaud, S., Ford, A.P.D.W., and Eglen, R.M. Evidence for purinergic neurotransmission in the urinary bladder of pithed rats. Eur. J. Pharmacol. 349(1): 75-82, 1998.                          |


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>850865.90015</b>	Application Number <b>10/620,520</b>
		Applicant(s) <b>BEAUDOIN, A.L. et al.</b>	
		Filing Date <b>July 16, 2003</b>	Group Art Unit


  

*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
		
	28.	Dunwiddie, T.V., Abbracchio, M.P., Bischofberger, N., Brundage, J.M., Buell, G., Collo, G., Corsi, C., Diao, L., Kawashima, E., Jacobson, K.A., Latini, S., Lin, R.C.S., North, R.A., Pazzagli, M., Pedata, F., Pepeu, G.C., Proctor, W.R., Rassendren, F., Surprenant, A., and Cattabeni, F. Purinoceptors in the central nervous system. <i>Drug Dev. Res.</i> 39(3-4): 361-370, 1996.
	29.	Burnstock, G., and Wood, J.N. Purinergic receptors: Their role in nociception and primary afferent neurotransmission. <i>Curr. Opin. in Neurobiol.</i> 6(4): 526-532, 1996.
	30.	Von Kugelgen, I. Purinoceptors modulating the release of noradrenaline. <i>J. Autonomic. Pharmacol.</i> 14(1): 11-12, 1994.
	31.	Beaudoin, A.R., Sévigny, J., and Picher, M. ATP diphosphohydrolases, apyrases and nucleotide phosphohydrolases: biochemical properties and functions. In: <i>Biomembrane</i> , vol. 5; Lee, A.G., Ed.; Greenwich, CT: JAI, pp. 369-401, 1996.
	32.	P. 1072 Sigma-Aldrich catalogue "Bioactive Peptides".
	33.	Beaudoin, A.R., Grondin, G., Enjyoji, K., Robson, S.C., Sévigny, J., Fischer, B., and Gendron, F.-P. Physiological role of NTPDases (ATP diphosphohydrolases) in mammals. <i>Proceeding of the 2nd International Workshop on ecto-ATPase and related nucleotidases</i> . Diepenbeek, Belgium, 14-18 June 1999. Vanduffel L., and Lemmens R., Eds. Shaker Publishing B.V., The Netherlands; pp. 125-135, 2000.
	34.	Plesner, L. Ecto-ATPases: identities and functions. <i>Int. Rev. Cytol.</i> 158: 141-214, 1995.
	35.	Vlajkovic, S.M., Thorne, P.R., Hously, G.D., Munoz, D.J.B., and Kendrick, I.S. Ecto-nucleotidases terminate purinergic signalling in the cochlear endolymphatic compartment. <i>Neuroreport</i> 9: 1559-1565, 1998.
	36.	Zimmermann, H. 5'-Nucleotidase: molecular structure and functional aspects. <i>Biochem. J.</i> 285: 345-365, 1992.
	37.	Laliberté, J.-F. and Beaudoin A.R. Sequential hydrolysis of the gamma- and beta-phosphate groups of ATP by the ATP diphosphohydrolase from pig pancreas. <i>Biochim. Biophys. Acta</i> 742(1):9-15, 1983.
	38.	Côté, Y.P., Pavate C.T. and Beaudoin A.R. The control of nucleotides in blood vessels: Role of the ATP diphosphohydrolase (Apyrase). <i>Curr. Top. Pharmacol.</i> 1:83-92, 1992.
	39.	Sévigny J., Levesque F.P., Grondin G. and Beaudoin A.R. Purification of the blood vessel ATP diphosphohydrolase, identification and localization by immunological techniques. <i>Biochim. Biophys. Acta</i> 1334: 73-88, 1997.
EXAMINER		DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

850865.90015

Application Number

10/620,520

Applicant(s)

BEAUDOIN, A.L. et al.

Filing Date

July 16, 2003

Group Art Unit

\*EXAMINER  
INITIAL


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- |     |   |
|-----|---|
| 40. | LeBel D., Poirier G.G., Phaneuf, S., St-Jean P., Laliberté J.-F. and Beaudoin A.R. Characterization and purification of a calcium sensitive ATP diphosphohydrolase from the pig pancreas. J. Biol. Chem. 255: 1227-1233, 1980.  |
| 41. | Sévigny, J., Côté, Y.P. and Beaudoin, A.R. Purification of pancreas type I ATP diphosphohydrolase and identification by affinity labelling with 5'-p-fluorosulfonylbenzoyladenine ATP analog. Biochem J. 312: 351-356, 1995.  |
| 42. | Christoforidis, S., Papamarcaki, T., Galaris, D., Kellner, R. and Tsolas, O. Purification and properties of human placental ATP diphosphohydrolase. Eur. J. Biochem. 234: 66-74, 1995.  |
| 43. | Kaczmarek, E., Koziack, K., Sévigny, J., Siegel, J.B., Anrather, J., Beaudoin, A.R., Back, F.H., Robson, S.C. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J. Biol. Chem. 271: 33116-33122, 1996.   |
| 44. | Maliszewski, C.R., Delespesse, G.J.T., Schoenborn, M.A., Armitage, R.J., Fanslow, W.C., Nakajima, T., Baker, E., Sutherland, G.R., Poindexter, K., Birks, C., Alpert, A., Friend, D., Gimpel, S.D., Gayle III, R.B. The CD39 lymphoid cell activation antigen: Molecular cloning and structural characterization. J. Immunol. 153: 3574-3583, 1994. |
| 45. | Wang, T.-F., Guidotti, G. CD39 is an ecto-(Ca <sup>2+</sup> , Mg <sup>2+</sup> )-ATPase. J. Biol. Chem. 271: 9898-9901, 1996.   |
| 46. | Barcellos, C.K., Schetinger M.R.C., Battastini A.M.O., Silva L.B., Dias R.D., Sarkis J.J.F. Inhibitory effect of cadmium acetate on synaptosomal ATP diphosphohydrolase (EC 3.6.1.5; ATPase) from adult rat cerebral cortex. Braz. J. Med and Biol. Res. 27(5): 1111-1115, 1994.  |
| 47. | Côté, Y.P., Ouellet, S., and Beaudoin, A.R. Kinetic properties of type-II ATP diphosphohydrolase from the tunica media of the bovine aorta. Biochim. Biophys. Acta 1160(3): 246-250, 1992.  |
| 48. | Picher, M., Sévigny, J., D'Orléans-Juste, P., Beaudoin A.R. Hydrolysis of P2-purinoceptor agonists by a purified ectonucleotidase from the bovine aorta, the ATP diphosphohydrolase. Biochem. Pharmacol. 51: 1453-1460, 1996.   |
| 49. | Westfall, T.D., Kennedy, C., and Sneddon, P. The ecto-ATPase inhibitors ARL 67156 enhances parasympathetic neurotransmission in the guinea-pig urinary bladder. Eur. J. Pharmacol. 329(2-3): 169-173, 1997.   |
| 50. | Crack, B.E., Pollard, C.E., Beukers, M.W., Roberts, S.M., Hunt, S.F., Ingall, A.H., McKechnie, K.C.W., Ijzerman, A.P., and Leff, P. Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br. J. Pharmacol. 114(2): 475-481, 1995.  |
| 51. | Chen, B.C., Lee, C.-M. and Lin W.-W. Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C-6 glioma cells and RAW 264.7 macrophages. Br. J. Pharmacol. 119(8): 1628-1634, 1996.   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>850865.90015</b>	Application Number <b>10/620,520</b>
		Applicant(s) <b>BEAUDOIN, A.L. et al.</b>	
*EXAMINER INITIAL		Filing Date <b>July 16, 2003</b>	Group Art Unit
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
52.		Kennedy, C., Westfall, T.D., and Sneddon, P. Modulation of purinergic neurotransmission by ecto-ATPase. Sem. Neurosci. 8(4): 195-199, 1996.	
53.		Fischer, B., Chulkin, A., Boyer, J.L., Harden, K.T., Gendron, F.-P., Beaudoin, A.R., Chapal, J., Hillaire-Buys, D., Petit, P. 2-thioether 5'-O-(1-thiotriphosphate) adenosine derivatives as new insulin secretagogues acting through P2Y-receptors. J. Med. Chem. 42: 3636-3646, 1999.	
54.		Bültmann, R., Wittenburg, H., Pause, B., Kurz, G., Nickel, P., and Starke, K. P2-purinoceptors antagonists; III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn-Schmiedeberg's Arch. Pharmacol. 354: 498-504, 1996.	
55.		Tuluc, F., Bültmann, R., Glänzel, M., Wilhelm Frahm, A., and Starke, K. P2-receptor antagonists: IV. Blockade of P2 receptor subtypes and ecto-nucleotidases by compounds related to reactive blue 2. Naunyn-Schmiedeberg's Arch. Pharmacol. 357: 111-120, 1998.	
56.		Bültmann, R., and Starke, K. Reactive red 2: a P2Y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase. Naunyn-Schmiedeberg's Arch. Pharmacol. 352: 477-482, 1995.	
57.		Wittenburg, H., Bültmann, R., Pause, B., Ganter, C., Kurz, G., and Starke, K. P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans Blue and trypan blue. Naunyn-Schmiedeberg's Arch. Pharmacol. 354: 491-497, 1996.	
58.		Bültmann, R., Pause, B., Wittenburg, H., Kurz, G., and Starke, K. P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates. Naunyn-Schmiedeberg's Arch. Pharmacol. 354: 481-490, 1996.	
59.		Bonan, C.D., Battastini, A.M.O., Schetinger, M.R.C., Moreira, C.M., Frassetto, S.S., Dias, R.D., and Sarkis, J.J.F. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA) on ATP diphosphohydrolase (EC 3.6.1.5) and 5'-nucleotidases (EC 3.1.3.5) from rat brain synaptosomes. Gen. Pharmac. 28(5): 761-766, 1997.	
60.		Gendron, F.-P., Halbfinger E., Fischer B., Duval M., D'Orleans-Juste P. and Beaudoin, A.R. Novel inhibitors of nucleoside triphosphate diphosphohydrolases: Chemical Synthesis and Biochemical and Pharmacological Characterizations. J. Med.Chem 43(11): 2239-2244, 2000.	
61.		Fischer, B., Boyer, J.L., Hoyle, C.H.V., Ziganshin, A.U., Brizzolara, A.L., Knight, G.E., Zimmet, J., Burnstock, G., Harden, T.K. and Jacobson, K.A. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J. Med. Chem. 36: 3937-3946, 1993.	
62.		Baykov A.A., Evtushenko O.A. and Avaeve S.M. A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal Biochem. 171: 266-270, 1988.	
63.		Bradord M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.	
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

850865.90015

Application Number

10/620,520

Applicant(s)

BEAUDOIN, A.L. et al.

Filing Date

July 16, 2003

Group Art Unit

\*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

64.

Berthiaume, N., Claing, A., Reginald, D., Warner, T.D., D'Orléans-Juste, P. Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. Br. J. Pharmacol. 115: 1319-1325, 1995.

65.

Halbfinger, E., Major, D.T., Ritzmann, M., Ubl, J., Reiser, G., Boyer, J.L., Harden, K.T., Fischer, B. Molecular recognition of modified adenine nucleotides by the P2Y1-receptor. Part I. A synthetic, biochemical, and NMR approach. J. Med. Chem. 42: 5325-5337, 1999.

66.

Major, D.T., Halbfinger, E. and Fischer, B. Molecular recognition of modified adenine nucleotides by the P2Y1-receptor. II. A computational approach. J. Med. Chem 42: 5338-5347, 1999.

67.

Van Rhee, A.M., Fischer, B., Van Galen, P.J.M., Jacobson, K.A. Modelling the P2Y purinoceptor using rhodopsin as template. Drug Design and Discovery 13: 133-154, 1995.

68.

Hirst, G.D.S., Jobling, P. The distribution of gamma-adrenoceptors and P2 purinoceptors in mesenteric arteries and veins of the guinea-pig. Br. J. Pharmacol. 96: 993-999, 1989.

69.

Onaka, U., Fujii, K., Abe, I., Fujishima, M. Enhancement by exogenous and locally generated angiotensin II of purinergic neurotransmission via angiotensin type 1 receptor in the guinea-pig isolated mesenteric artery. Br. J. Pharmacol. 122: 942-948, 1997.

70.

Fujii, K. Evidence for adenosine triphosphate as an excitatory transmitter in guinea-pig, rabbit and pig urinary bladder. J. Physiol. 404: 39-52, 1988.

71.

Ishikawa, S. Actions of ATP and alpha, beta-methylene ATP on neuromuscular transmission and smooth muscle membrane of the rabbit and guinea-pig mesenteric arteries. Br. J. Pharmacol. 86: 777-787, 1985.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.